Opinion

Video

Fruquintinib in mCRC: Key Insights From FRESCO-2

Medical experts highlight key data from the FRESCO-2 trial on fruquintinib for previously treated metastatic colorectal cancer, focusing on study population, efficacy, and safety, and discuss real-world experience with fruquintinib compared with trial outcomes.

Video content above is prompted by the following:

  1. New to our arsenal of drugs is fruquintinib, an additional option for previously treated metastatic colorectal cancer based on the FRESCO-2 data. What are some highlights of this data in terms of the study population, efficacy, and safety?
  2. Include in this discussion that all patients previously received regorafenib or FTD/TPI.
  3. What has been your experience using fruquintinib in practice, and how do patient outcomes compare with what was seen in FRESCO-2?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Andrew Kuykendall, MD, Moffitt Cancer Center
Dr Sundar Jagannath
4 experts in this video
4 experts in this video
Screenshot of a webinar panel discussion with Viet Le, PA-C; Nathan Wong, PhD, MPH; Alison Bailey, MD; and Martha Gulati, MD, MS
World Hepatitis Day graphic | Image Credit: uazzal - stock.adobe.com
2 experts in this video
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo